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Decreased Susceptibility of Staphylococcus aureus
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Peptides
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Staphylococcus aureus is a frequent resident of human nose and skin in many individuals, but it is also able to
cause a variety of serious infections including those of the skin and soft tissue. There is increasing evidence that
particularly persistent, relapsing, and difficult-to-treat infections caused by S. aureus are associated with the
formation of the small-colony variant (SCV) phenotype. The aim of this study was to investigate the hypothesis
that (i) skin-derived antimicrobial peptides (AMPs) exhibit a reduced activity against SCVs and (ii) that switching
into the SCV phenotype may endow S. aureus with a decreased susceptibility toward the killing activity of human
stratum corneum. Here, we show that clinically derived S. aureus SCVs are less susceptible to the bactericidal
activity of different human skin-derived AMPs as compared with their isogenic corresponding wild-type strains.
Similarly, a S. aureus hemBmutant displaying the SCV phenotype was less susceptible to the antimicrobial activity
of AMPs than its hemB-complemented mutant. These findings were accompanied by a higher resistance of SCVs
to the killing activity of human stratum corneum. Switching into the SCV phenotype may help S. aureus to
subvert cutaneous innate defense, thus contributing to the establishment and persistence of infection.
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INTRODUCTION
The Gram-positive opportunistic bacterium Staphylococcus
aureus is a frequent resident of human skin and nose
microbiota in many individuals (Wos-Oxley et al., 2010),
but it also has a major impact as a causative agent of a variety
of serious infections including those of the skin and soft tissue
(Iwatsuki et al., 2006; Miller and Kaplan, 2009). There is
increasing evidence that particularly persistent, relapsing, and
difficult-to-treat infections caused by S. aureus are associated
with the formation of the small-colony variant (SCV)
phenotype (Proctor et al., 2006; Vaudaux et al., 2006;
von Eiff and Becker, 2007). SCVs generally have a longer
generation time and are named because of their slow growth
leading to small colonies on agar plates. As SCVs often need
several days to become visible on agar plates, they can be
easily missed by routine microbial diagnostic procedures
(Proctor et al., 2006; Vaudaux et al., 2006). Being
internalized in the host cell environment, S. aureus is able
to switch from the wild-type phenotype to a SCV phenotype,
thus making it possible to escape host defense responses and
to spread the infection (Tuchscherr et al., 2011; von Eiff et al.,
2001). The switch to an SCV phenotype is associated with
complex physiological and metabolic changes mainly based
on defects in electron transport or in biosyn-
thesis of thymidine (Proctor et al., 2006; Kriegeskorte et al.,
2011). The phenotype switching enables S. aureus to hide
inside host cells, leading to escape from immune responses
and those antibiotics without intracellular activity (von Eiff
et al., 2006; Garcia et al., 2013).
SCVs have been associated with various chronic, recurrent,
and persistent infections including soft-tissue and skin infec-
tions (von Eiff et al., 2006; Melter and Radojevic, 2010). As the
epidermis is the first barrier that S. aureus has to overcome in
order to enter and persist in the host, we hypothesize that
SCVs may subvert cutaneous defense by a decreased suscep-
tibility toward skin-derived AMPs.
RESULTS AND DISCUSSION
The aim of this study was to investigate the hypothesis that
SCVs display a higher resistance toward the action of skin-
derived antimicrobial peptides (AMPs). To this end, we
analyzed the activity of the skin-derived AMPs human beta-
defensin (hBD)-2 and -3, RNase 7, and LL-37 against various
SCVs. We choose these AMPs because they are all major skin-
derived AMPs (Harder et al., 2007; Gallo and Hooper, 2012),
and they are all present in the stratum corneum, as demon-
strated by immunohistochemistry (Figure 1). In particular,
RNase 7 and hBD-3 have been reported to be principle AMPs
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released by keratinocytes to control the growth of S. aureus
(Kisich et al., 2007; Simanski et al., 2010).
We tested these AMPs against three natural SCV isolates
recovered from clinical specimens in parallel with their
isogenic corresponding wild-type strains. The use of a micro-
dilution assay with different concentrations of AMPs revealed
highest activity of hBD-3 against wild-type S. aureus followed
by LL-37, RNase 7, and hBD-2 (Table 1). In contrast, all SCVs
showed a decreased susceptibility toward these AMPs. HBD-3
demonstrated a moderate reduction of its capability to kill
SCVs compared with wild-type S. aureus. RNase 7 and hBD-2
showed a strongly reduced antimicrobial activity against
SCVs. Similarly, LL-37 displayed a decreased activity against
all clinical SCVs (Table 1).
It is obvious that hBD-3 killed those isolates that display
the SCV phenotype more efficiently than the other AMPs,
including its beta-defensin family member hBD-2. It is known
that hBD-2 is in general less active against S. aureus, and this
may be the reason why hBD-2 is also less active against SCVs.
It has been suggested that the capacity of hBD-3 to form
dimers and its high positive surface charge are responsible for
its high activity against S. aureus (Schibli et al., 2002). In
addition, its special mode of action by interfering with the
S. aureus cell wall biosynthesis machinery (Sass et al., 2010)
may also explain its augmented activity against S. aureus and,
therefore, also against SCVs. Nevertheless, hBD-3 showed also
a decreased activity against all tested SCVs as compared with
the corresponding wild-type strains (Table 1).
To further verify the reduced activity of AMPs against SCVs,
we used a strain pair representing (i) a genetically defined
mutant constructed by interrupting one of the hemin biosyn-
thetic genes, hemB, that displays the SCV phenotype, and (ii)
its hemB-complemented mutant exhibiting the normal pheno-
type (von Eiff et al., 1997). Except LL-37, all AMPs exhibited
50 µm 50 µm
50 µm50 µm
Figure 1. Immunostaining of RNase 7, human beta-defensin (hBD)-2, hBD-3, and LL-37 in the stratum corneum. To demonstrate the presence of the investigated
antimicrobial peptides (AMPs) in the stratum corneum, we performed immunohistochemical staining of the AMPs using human skin biopsies derived from
the soles of the feet. RNase 7 (a), hBD-2 (b), hBD-3 (c), and LL-37 (d) all showed staining in the stratum corneum. Bars¼50mM.
Table 1. LD90 (lgml
 1)1 of the AMPs RNase 7, hBD-2, hBD-3, and LL-37 against SCV and corresponding wild-type
strains OM1, A22216, and OM299, as well as against a S. aureus hemB mutant and its hemB-complemented mutant
OM1 A22216 OM299 hemB
Wild-type SCV Wild-type SCV Wild-type SCV Complemented mutant Mutant
RNase 7 2.5–5 440 2.5–5 440 5–10 440 2.5–5 440
hBD-2 10–20 440 10–20 440 5–10 440 440 (10–20)2 440 (440)2
hBD-3 0.6–1.25 2.5–5 0.6–1.25 1.25–2.5 0.6–1.25 1.25–2.5 0.6–1.25 1.25–2.5
LL-37 2.5–5 5–10 2.5–5 10–20 1.25–2.5 10–20 5–10 5–10
Abbreviations: AMPs, antimicrobial peptides; hBD, human beta-defensin; LD, lethal dose; SCV, small-colony variant.
1Lethal dose (mg ml 1) to kill 90% of the bacteria.
2Lethal dose (mg ml 1) to kill 50% of the bacteria.
R Gla¨ser et al.
SCV and Antimicrobial Peptides
2348 Journal of Investigative Dermatology (2014), Volume 134
decreased antimicrobial activity against the hemB mutant as
compared with the hemB-complemented mutant (Table 1).
Taken together, our data indicate that skin-derived AMPs
generally exhibit a limited antimicrobial activity against SCVs.
To further evaluate the functional relevance of these find-
ings, we incubated stratum corneum extract (derived from
heel callus) with the different bacterial strains and analyzed
the killing activity of the extract. These experiments revealed a
significantly reduced activity of the stratum corneum extract
against all three clinical SCVs tested, as compared with the
corresponding wild-type S. aureus strains (Figure 2a–c). In
concordance with these findings, the hemB mutant displaying
the SCV phenotype was less susceptible to the killing activity
of the stratum corneum as compared with the hemB-comple-
mented strain (Figure 2d).
Our results demonstrate a reduced activity of human AMPs
against SCVs. The reduced activity of human skin-derived AMPs
against SCVs is accompanied by a decreased capability of the
stratum corneum to kill isolates exhibiting the SCV phenotype.
Recently, it has been demonstrated that the antimicrobial activity
of stratum corneum extract against S. aureus was in part
mediated by RNase 7 (Simanski et al., 2010). This suggests
that the observed antimicrobial activity of the stratum corneum
extract against S. aureus and S. aureus SCVs is mediated by
AMPs such as RNase 7. However, we cannot exclude that also
other antimicrobial factors in the stratum corneum (e.g.,
antimicrobial lipids, (Drake et al., 2008)) may contribute to the
observed antimicrobial activity of the stratum corneum extract.
The reason why SCVs are endowed with a higher resistance
toward the activity of AMPs is not clear. Most human AMPs,
including the AMP under investigation used in this study, are
cationic and therefore positively charged. It has been
suggested that the resistance of SCVs against positively
charged antimicrobial agents might be a result of a lower
electrochemical gradient across the bacterial cell membrane
(Sadowska et al., 2002). However, cationic AMPs do not
always exhibit a reduced activity against SCVs. Sadowska et al.
(2002) tested several cationic AMPs against SCVs, and they
found no significant differences in the susceptibility of normal
S. aureus and SCVs to the bactericidal activity of the frog-
derived cationic AMP magainin and the neutrophil-derived
alpha-defensin HNP-1. The susceptibility to the frog-derived
cationic AMP dermaseptin was even higher for SCVs (Sadowska
et al., 2002). In contrast, SCVs were more resistant toward the
fish-derived cationic AMP protamine (Sadowska et al., 2002),
toward the bovine-derived cationic AMP lactoferricin B
(Samuelsen et al., 2005), and toward the rabbit-derived
thrombin-induced platelet microbicidal protein (Koo et al.,
1996). Uncovering the exact resistance mode of SCVs toward
cationic antibiotics and AMPs is a future challenge to develop
novel antimicrobial agents with approved activity toward SCVs.
In summary, SCVs are less susceptible to the bactericidal
activity of different human skin-derived AMPs, and these
findings are associated with a higher resistance to the killing
activity of human stratum corneum. Switching into the SCV
phenotype may help S. aureus subvert cutaneous innate
defense, thus contributing to the establishment and persistence
of infection.
MATERIALS AND METHODS
Immunohistochemistry
To investigate the presence of AMPs in the stratum corneum, we
performed immunohistochemistry using formalin-fixed, paraffin-
embedded skin samples derived from the soles of patients (n¼ 3)
undergoing surgery of benign skin disorders (moles) after having given
informed consent (Kiel, AZ A104/06). Immunohistochemistry was
performed as described (Harder et al., 2010; Wittersheim et al., 2013)
using antibodies against hBD-2 (Peprotech, Hamburg, Germany),
hBD-3 (Acris Antibodies, Herford, Germany), LL-37 (Innovagen;
Lund, Sweden), and RNase 7 (Ko¨ten et al., 2009).
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Figure 2. Decreased susceptibility of S. aureus small-colony variants (SCVs) to the killing activity of human stratum corneum extract. Various dilutions of stratum
corneum extract were tested in a microdilution assay for their capacity to kill various SCVs. Bacteria were incubated together with the indicated dilutions of
stratum corneum extract for 3 hours. After 3 hours, serial dilutions were plated on trypticase soy broth agar plates, and colony-forming units were counted after
incubation for up to 4 days. The growth control after 3 hours without stratum corneum extract was set as 100%. Bars are means±SD representative of at least two
independent experiments (*Po0.05, **Po0.01; Student’s t-test). Shown are the S. aureus SCV clinical isolates OM1 (a), OM299 (b), and A22216 (c) and their
corresponding isogenic wild types. In addition, a S. aureus hemB mutant displaying the SCV phenotype and its hemB-complemented mutant were used (d).
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SCVs of Staphylococcus aureus
We used three natural SCV isolates recovered from clinical specimens
in parallel with their isogenic corresponding wild-type strains.
Genetic relatedness between clinical SCVs and their corresponding
parental strains displaying the normal phenotype was determined by
pulsed-field gel electrophoresis), as described elsewhere (von Eiff
et al., 2001).
Furthermore, a genetically constructed strain pair consisting of a
site-directed S. aureus hemB mutant and its hemB-complemented
mutant was included (von Eiff et al., 1997). The hemB mutant displays
the SCV phenotype and represents a genetically defined mutant
constructed by interrupting one of the hemin biosynthetic genes. As
a corresponding control, the hemB-complemented mutant, which
exhibits the normal phenotype, was used (von Eiff et al., 1997).
Antimicrobial activity of AMP and stratum corneum extract
toward SCVs
We used a microdilution assay to test the antimicrobial activity of the
AMPs hBD-2 and -3, RNase 7, and LL-37 against the SCVs. The
microdilution assay was performed by incubating bacteria and serial
dilutions of AMPs for 3 hours in sodium phosphate buffer (pH 7.2)
containing 1% trypticase soy broth. The remaining bacteria were
determined by plating on trypticase soy broth (Sigma, Munich,
Germany) agar plates and counting colony-forming units after
incubation at 37 oC for up to 4 days. Recombinant hBD-2, hBD-3,
and RNase 7 were produced in E. coli as described (Harder et al.,
2001; Ko¨ten et al., 2009; Sahly et al., 2003). Synthetic LL-37 was
obtained from Innovagen.
Stratum corneum derived from healthy persons’ heel callus was
extracted as described (Schro¨der, 2010) and diafiltered against 10 mM
sodium phosphate buffer (pH 7.2). To analyze the antimicrobial
activity of the stratum corneum extract against S. aureus wild-type
and SCV strains, various dilutions of this extract were incubated in a
microdilution assay, as described above.
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